Apoptosis and plastic surgery

Plastic and Reconstructive Surgery

Volumn 111, Issue 4, 2003, Pages 1481-1496

  Gastman, Brian R ^a,b   Futrell, J William ^a   Manders, Ernest K ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE; PROTEIN BCL 2;

AGING; ALLOGRAFT; ALLOTRANSPLANTATION; APOPTOSIS; ARTICLE; CELL DEATH; CRANIOFACIAL DEVELOPMENT; GRAFT SURVIVAL; HOMEOSTASIS; HUMAN; LIMB DEVELOPMENT; NONHUMAN; PATHOPHYSIOLOGY; PLASTIC SURGERY; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; STEM CELL TRANSPLANTATION; TISSUE FLAP; WOUND HEALING;

AGING; ANIMALS; APOPTOSIS; CRANIOFACIAL ABNORMALITIES; EXTREMITIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; STEM CELLS; SURGICAL FLAPS; TISSUE ENGINEERING; TRANSPLANTATION, HOMOLOGOUS; WOUND HEALING;

EID: 0037375746     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PRS.0000049639.64947.EF     Document Type: Article

References (207)

1. Kerr, J. F., Wyllie, A. H., and Currie, A. R. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26: 239, 1972.
2. Kothakota, S., Azuma, T., Reinhard, C., et al. Caspase-3-generated fragment of gelsolin: Effector of morpho logical change in apoptosis. Science 278: 294, 1997.
3. Frisch, S. M., and Screaton, R. A. Anoikis mechanisms. Curr. Opin. Cell Biol. 13: 555, 2001.
4. Maruyama, W., Irie, S., and Sato, T. A. Morphological changes in the nucleus and actin cytoskeleton in the process of Fas-induced apoptosis in Jurkat T cells. Histochem. J. 32: 495, 2000.
5. Nicholson, D. W. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ. 6: 1028, 1999.
6. Thornberry, N. A., and Lazebnik, Y. Caspases enemies within. Science 281: 1312, 1998.
7. Gastman, B. R. Apoptosis and its clinical impact. Head Neck 23: 409, 2001.
8. Honig, L. S., and Rosenberg, R. N. Apoptosis and neurologic disease. Am. J. Med. 108: 317, 2000.
9. Higami, Y., and Shimokawa, I. Apoptosis in the aging process. Cell Tissue Res. 301: 125, 2000.
10. Narula, J., Pandey, P., Arbustini, E., et al. Apoptosis in heart failure: Release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy (see comments). Proc. Natl. Acad. Sci. U.S.A. 96: 8144, 1999.
11. Evan, G. I., and Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer. Nature 411: 342, 2001.
12. Fisher, G. H., Rosenberg, F. J., Straus, S. E., et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81: 935, 1995.
13. Rathmell, J. C., and Thompson, C. B. Pathways of apoptosis in lymphocyte development, homeostasis, and disease. Cell 109 (Suppl.): S97, 2002.
14. Vaux, D. L., and Korsmeyer, S. J. Cell death in development. Cell 96: 245, 1999.
15. Nicholson, D. W. From bench to clinic with apoptosis-based therapeutic agents. Nature 407: 810, 2000.
16. Clarke, P. G., and Clarke, S. Nineteenth century research on naturally occurring cell death and related phenomena. Anat. Embryol. (Berl.) 193: 81, 1996.
17. Ellis, H. M., and Horvitz, H. R. Genetic control of programmed cell death in the nematode C. elegans. Cell 44: 817, 1986.
18. Hengartner, M. O., and Horvitz, H. R. Programmed cell death in Caenorhabditis elegans. Curr. Opin. Genet. Dev. 4: 581, 1994.
19. Horvitz, H. R., Shaham, S., and Hengartner, M. O. The genetics of programmed cell death in the nematode Caenorhabditis elegans. Cold Spring Harb. Symp. Quant. Biol. 59: 377, 1994.
20. Conradt, B., and Horvitz, H. R. The C. elegans protein EGL-1 is required for programmed cell death and interacts with the Bcl-2-like protein CED-9. Cell 93: 519, 1998.
21. Yuan, J., Shaham, S., Ledoux, S., Ellis, H. M., and Horvitz, H. R. The C elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell 75: 641, 1993.
22. Zheng, T. S., and Flavell, R. A. Divinations and surprises: Genetic analysis of caspase function in mice. Exp. Cell Res. 256: 67, 2000.
23. Los, M., Wesselborg, S., and Schulze-Osthoff, K. The role of caspases in development, immunity, and apoptotic signal transduction: Lessons from knockout mice. Immunity 10: 629, 1999.
24. Barinaga, M. Death by dozens of cuts. Science 280: 32, 1998.
25. Stennicke, H. R., and Salvesen, G. S. Caspases: Controlling intracellular signals by protease zymogen activation. Biochim. Biophys. Acta 1477: 299, 2000.
26. Salvesen, G. S., and Dixit, V. M. Caspase activation: The induced-proximity model. Proc. Natl. Acad. Sci. U.S.A. 96: 10964, 1999.
27. Hengartner, M. O. The biochemistry of apoptosis. Nature 407: 770, 2000.
28. Enari, M., Sakahira, H., Yokoyama, H., Okawa, K., Iwamatsu, A., and Nagata, S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD (see comments). Nature 391: 43, 1998. (Published erratum appears in 393: 396, 1998.)
29. Rudel, T., and Bokoch, G. M. Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2. Science 276: 1571, 1997.
30. Wolf, B. B., and Green, D. R. Suicidal tendencies: Apoptotic cell death by caspase family proteinases, J. Biol. Chem. 274: 20049, 1999.
31. Tsujimoto, Y., Cossman, J., Jaffe, E., and Croce, C. M. Involvement of the bcl-2 gene in human follicular lymphoma. Science 228: 1440, 1985.
32. Reed, J. C., Cuddy, M., Slabiak, T., Croce, C. M., and Nowell, P. C. Oncogenic potential of bcl-2 demonstrated by gene transfer. Nature 336: 259, 1988.
33. Liu, Y. J., Mason, D. Y., Johnson, G. D., et al. Germinal center cells express bcl-2 protein after activation by signals which prevent their entry into apoptosis. Eur. J. Immunol. 21: 1905, 1991.
34. Sentman, C. L., Shutter, J. R., Hockenbery, D., Kanagawa, O., and Korsmeyer S. J. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 67: 879, 1991.
35. Hengartner, M. O., and Horvitz, H. R. C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2. Cell 76: 665, 1994.
36. Shimizu, S., Eguchi, Y., Kamiike, W., Matsuda, H., and Tsujimoto, Y. Bcl-2 expression prevents activation of the ICE protease cascade. Oncogene 12: 2251, 1996.
37. Puthalakath, H., Huang, D. C., O'Reilly, L. A., King, S. M., and Strasser, A. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol. Cell 3: 287, 1999.
38. Wang, G. Q., Gastman, B. R., Wieckowski, E., et al. A role for mitochondial Bak in apoptotic response to anticancer drugs. J. Biol. Chem. 276: 34307, 2001.
39. Wei, M. C., Zong, W. X., Cheng, E. H., et al. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science 292: 727, 2001.
40. Gross, A., McDonnell, J. M., and Korsmeyer, S. J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13: 1899, 1999.
41. Zha, J., Harada, H., Osipov, K., Jockel, J., Waksman, G., and Korsmeyer, S. J. BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity. J. Biol. Chem. 272: 24101, 1997.
42. Kroemer, G., Zamzami, N., and Susin, S. A. Mitochondrial control of apoptosis. Immunol. Today 18: 44, 1997.
43. Muchmore, S. W., Sattler, M., Liang, H., et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381: 335, 1996.
44. Harris, M. H., and Thompson, C. B. The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ. 7: 1182, 2000.
45. Vander Heiden, M. G., Chandel, N. S., Williamson, E. K., Schumacker, P. T., and Thompson, C. B. Bcl-X(L) regulates the membrane potential and volume homeostasis of mitochondria. Cell 91: 627, 1997.
46. Luo, X., Budihardjo, I., Zou, H., Slaughter, C., and Wang, X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481, 1998.
47. Li, H., Zhu, H., Xu, C. J., and Yuan, J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491, 1998.
48. Gross, A., Yin, X. M., Wang, K., et al. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J. Biol. Chem. 274: 1156, 1999.
49. Green, D. R. Apoptotic pathways: The roads to ruin. Cell 94: 695, 1998.
50. Korsmeyer, S. J., Shutter, J. R., Veis, D. J., Merry, D. E., and Oltvai, Z. N. Bcl-2/Bax: A rheostat that regulates an anti-oxidant pathway and cell death. Semin. Cancer Biol. 4: 327, 1993.
51. Voehringer, D. W., and Meyn, R. E. Redox aspects of Bcl-2 function. Antioxid. Redox Signal 2: 537, 2000.
52. Adams, J. M., and Cory, S. The Bcl-2 protein family: Arbiters of cell survival. Science 281: 1322, 1998.
53. Hu, Y., Benedict, M. A., Wu, D., Inohara, N., and Nunez, G. Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc. Natl. Acad. Sci. U.S.A. 95: 4386, 1998.
54. Moriishi, K., Huang, D. C., Cory, S., and Adams, J. M. Bcl-2 family members do not inhibit apoptosis by binding the caspase activator Apaf-1. Proc. Natl. Acad. Sci. U.S.A. 96: 9683, 1999.
55. Benedict, M. A., Hu, Y., Inohara, N., and Nunez, G. Expression and functional analysis of Apaf-1 isoforms: Extra Wd-40 repeat is required for cytochrome c binding and regulated activation of procaspase-9. J. Biol. Chem. 275: 8461, 2000.
56. Zou, H., Henzel, W. J., Liu, X., Lutschg, A., and Wang, X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3 (see comments). Cell 90: 405, 1997.
57. Zou, H., Li, Y., Liu, X., and Wang, X. An APAF-1,cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem. 274: 11549, 1999.
58. Du, C., Fang, M., Li, Y., Li, L., and Wang, X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102: 33, 2000.
59. Suzuki, Y., Imai, Y., Nakayama, H., Takahashi, K., Takio, K., and Takahashi, R. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol. Cell 8: 613, 2001.
60. Goyal, L. Cell death inhibition: Keeping caspases in check. Cell 104: 805, 2001.
61. Green, D. R. Apoptotic pathways: Paper wraps stone blunts scissors. Cell 102: 1, 2000.
62. Green, D. R., and Reed, J. C. Mitochondria and apoptosis. Science 281: 1309, 1998.
63. Soengas, M. S., Capodieci, P., Polsky, D., et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409: 207, 2001.
64. Locksley, R. M., Killeen, N., and Lenardo, M. J. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 104: 487, 2001.
65. Baker, S. J., and Reddy, E. P. Modulation of life and death by the TNF receptor superfamily. Oncogene 17: 3261, 1998.
66. Chinnaiyan, A. M., O'Rourke, K., Tewari, M., and Dixit, V. M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81: 505, 1995.
67. Peter, M. E., and Krammer, P. H. Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr. Opin. Immunnol. 10: 545, 1998.
68. Nagata, S. Apoptosis by death factor. Cell 88: 355, 1997.
69. Krammer, P. H. CD95's deadly mission in the immune system. Nature 407: 789, 2000.
70. Adachi, M., Suematsu, S., Kondo, T., et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat. Genet. 11: 294, 1995.
71. Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., and Ferguson, T. A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270: 1189, 1995.
72. Gastman, B. R., Atarshi, Y., Reichert, T. E., et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res. 59: 5356, 1999.
73. Feuerstein, G. Z., and Young, P. R. Apoptosis in cardiac diseases: Stress- and mitogen-activated signaling pathways. Cardiovasc. Res. 45: 560, 2000.
74. Martinez, O. M., and Krams, S. M. Involvement of Fas-Fas ligand interactions in graft rejection. Int. Rev. Immunol. 18: 527, 1999.
75. Berke, G. The CTL's kiss of death. Cell 81: 9, 1995.
76. Wing, J. P., Schreader, B. A., Yokokura, T., et al. Drosophila Morgue is an F box/ubiquitin conjugase domain protein important for grim-reaper mediated apoptosis. Nat. Cell Biol. 4: 451, 2002.
77. Wilson, R., Goyal, L., Ditzel, M., et al. The DIAP1 RING finger mediates ubiquitination of Dronc and is indispensable for regulating apoptosis. Nat. Cell Biol. 4: 445, 2002.
78. Holley, C. L., Olson, M. R., Colon-Ramos, D. A., and Kornbluth, S. Reaper eliminates IAP proteins through stimulated IAP degradation and generalized translational inhibition. Nat. Cell Biol. 4: 439, 2002.
79. Ryoo, H. D., Bergmann, A., Gonen, H., Ciechanover, A., and Steller, H. Regulation of Drosophila IAP1 degradation and apoptosis by reaper and ubcD1. Nat. Cell Biol. 4: 432, 2002.
80. Hays, R., Wickline, L., and Cagan, R. Morgue mediates apoptosis in the Drosophila melanogaster retina by promoting degradation of DIAP1. Nat. Cell Biol. 4: 425, 2002.
81. Yoo, S.J., Huh, J. R., Muro, I., et al. Hid, Rpr and Grim negatively regulate DIAP1 levels through distinct mechanisms. Nat. Cell Biol. 4: 416, 2002.
82. Steller, H. Drosophila p53: Meeting the Grim Reaper. Nat. Cell Biol. 2: E100, 2000.
83. Nicholson, D. W. From bench to clinic with apoptosis-based therapeutic agents. Nature 407: 810, 2000.
84. Lockshin, R. A., and Williams, C. M. Programmed cell death: V. Cytolytic enzymes in relation to the breakdown of the intersegmental muscles of silkmoths. J. Insect Physiol. 11: 831, 1965.
85. Kimura, S., and Shiota, K. Sequential changes of programmed cell death in developing fetal mouse limbs and its possible roles in limb morphogenesis. J. Morphol. 229: 337, 1996.
86. Rice, D. P., Kim, H. J., and Thesleff, I. Apoptosis in murine calvarial bone and suture development. Eur. J. Oral Sci. 107: 265, 1999.
87. Schorle, H., Meier, P., Buchert, M., Jaenisch, R., and Mitchell, P. J. Transcription factor AP-2 essential for cranial closure and craniofacial development. Nature 381: 235, 1996.
88. Shuler, C. F. Programmed cell death and cell transformation in craniofacial development. Crit. Rev. Oral Biol. Med. 6: 202, 1995.
89. Dry, G. M., Yasinskaya, Y. I., Williams, J. K., et al. Inhibition of apoptosis: A potential mechanism for syndromic craniosynostosis. Plast. Reconstr. Surg. 107: 425, 2001.
90. Wilkie, A. O., Slaney, S. F., Oldridge, M., et al. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat. Genet. 9: 165, 1995.
91. Witt, P. D., and MacArthur, C. A. Molecular biology and congenital hand anomalies: From molecules and mutations to man. Plast. Reconstr. Surg. 102: 2254, 1998.
92. Britto, J. A., Chan, J. C., Evans, R. D., Hayward, R. D., and Jones, B. M. Differential expression of fibroblast growth factor receptors in human digital development suggests common pathogenesis in complex acrosyndactyly and craniosynostosis. Plast. Reconstr. Surg. 107: 1331, 2001.
93. Mansukhani, A., Bellosta, P., Sahni, M., and Basilico, C. Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J. Cell Biol. 149: 1297, 2000.
94. Miho, Y., Kouroku, Y., Fujita, E., et al. bFGF inhibits the activation of caspase-3 and apoptosis of P19 embryonal carcinoma cells during neuronal differentiation. Cell Death Differ. 6: 463, 1999.
95. Dixon, J., Brakebusch, C., Fassler, R., and Dixon, M. J. Increased levels of apoptosis in the prefusion neural folds underlie the craniofacial disorder, Treacher Collins syndrome. Hum. Mol. Genet. 9: 1473, 2000.
96. Jiang, R., Lan, Y., Chapman, H. D., et al. Defects in limb, craniofacial, and thymic development in Jagged2 mutant mice. Genes Dev. 12: 1046, 1998.
97. Artavanis-Tsakonas, S., Rand, M. D., and Lake, R. J. Notch signaling: Cell fate control and signal integration in development. Science 284: 770, 1999.
98. Crocoll, A., Herzer, U., Ghyselinck, N. B., Chambon, P., and Cato, A. C. Interdigital apoptosis and downregulation of BAG-1 expression in mouse autopods. Mech. Dev. 111: 149, 2002.
99. Cecconi, F., Alvarez-Bolado, G., Meyer, B. I., Roth, K. A., and Gruss, P. Apaf1 (CED-4 homolog) regulates programmed cell death in mammalian development. Cell 94: 727, 1998.
100. Pang, C. Y. Ischemia-induced reperfusion injury in muscle flaps: Pathogenesis and major source of free radicals. J. Reconstr. Microsurg. 6: 77, 1990.
101. Hildeman, D. A., Mitchell, T., Teague, T. K., et al. Reactive oxygen species regulate activation-induced T cell apoptosis. Immunity 10: 735, 1999.
102. Saikumar, P., Dong, Z., Weinberg, J. M., and Venkatachalam, M. A. Mechanisms of cell death in hypoxia/reoxygenation injury. Oncogene 17: 3341, 1998.
103. Matsushita, K., Wu, Y., Qiu, J., et al. Fas receptor and neuronal cell death after spinal cord ischemia. J. Neurosci. 20: 6879, 2000.
104. Friedlander, R. M., Gagliardini, V., Hara, H., et al. Expression of a dominant negative mutant of interleukin-1 beta converting enzyme in transgenic mice prevents neuronal cell death induced by trophic factor withdrawal and ischemic brain injury. J. Exp. Med. 185: 933, 1997.
105. Mocanu, M. M., Baxter, G. F., and Yellon, D. M. Caspase inhibition and limitation of myocardial infarct size: Protection against lethal reperfusion injury. Br. J. Pharmacol. 130: 197, 2000.
106. Yaoita, H., Ogawa, K., Maehara, K., and Maruyama, Y. Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor (see comments). Circulation 97: 276, 1998.
107. Deune, E. G., Koopman, R., Smith, M. E., Hong, S. P., Ozbek, M. R., and Khouri, R. K. Prevention of ischemia-reperfusion injury with a synthetic metalloprotein superoxide dismutase mimic, SC52608. Plast. Reconstr. Surg. 98: 711, 1996.
108. Morris, S. F., Pang, C. Y., Lofchy, N. M., et al. Deferoxamine attenuates ischemia-induced reperfusion injury in the skin and muscle of myocutaneous flaps in the pig. Plast. Reconstr. Surg. 92: 120, 1993.
109. Hockenbery, D. M., Oltvai, Z. N., Yin, X. M., Milliman, C. L., and Korsmeyer, S. J. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75: 241, 1993.
110. Pepe, S. Mitochondrial function in ischaemia and reperfusion of the ageing heart. Clin. Exp. Pharmacol. Physiol. 27: 745, 2000.
111. White, B. C., Sullivan, J. M., DeGracia, D. J., et al. Brain ischemia and reperfusion: Molecular mechanisms of neuronal injury. J. Neurol. Sci. 179 (S. 1-2): 1, 2000.
112. Wang, B. H., Ye, C., Stagg, C. A., et al. Improved free musculocutaneous flap survival with induction of heat shock protein. Plast. Reconstr. Surg. 101: 776, 1998.
113. Buzzard, K. A., Giaccia, A. J., Killender, M., and Anderson, R.L. Heat shock protein 72 modulates pathways of stress-induced apoptosis. J. Biol. Chem. 273: 17147, 1998.
114. Mosser, D. D., Caron, A. W., Bourget, L., et al. The chaperone function of hsp70 is required for protection against stress-induced apoptosis. Mol. Cell Biol. 20: 7146, 2000.
115. Bruey, J. M., Ducasse, C., Bonniaud, P., et al. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat. Cell Biol. 2: 645, 2000.
116. Taub, P. J., Silver, L., and Weinberg, H. Plastic surgical perspectives on vascular endothelial growth factor as gene therapy for angiogenesis. Plast. Reconstr. Surg. 105: 1034, 2000.
117. Dimmeler, S., and Zeiher, A. M. Endothelial cell apoptosis in angiogenesis and vessel regression. Circ. Res. 87: 434, 2000.
118. O'Connor, D. S., Schechner, J. S., Adida, C., et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am. J. Pathol. 156: 393, 2000.
119. Nor, J. E., Christensen, J., Mooney, D. J., and Polverini, P. J. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am. J. Pathol. 154: 375, 1999.
120. Chavakis, E., and Dimmeler, S. Regulation of endothelial cell survival and apoptosis during angiogenesis. Arterioscler. Thromb. Vasc. Biol. 22: 887, 2002.
121. Witzenbichler, B., Asahara, T., Murohara, T., et al. Vascular endothelial growth factor-C (VEGF-C/ VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am. J. Pathol. 153: 381, 1998.
122. Emanueli, C., and Madeddu, P. Angiogenesis gene therapy to rescue ischaemic tissues: Achievements and future directions. Br. J. Pharmacol. 133: 951, 2001.
123. Isner, J. M., and Asahara, T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J. Clin. Invest. 103: 1231, 1999.
124. Taub, P. J., Marmur, J. D., Zhang, W. X., et al. Effect of time on the viability of ischemic skin flaps treated with vascular endothelial growth factor (VEGF) cDNA. J. Reconstr. Microsurg. 14: 387, 1998.
125. O'Reilly, M. S., Holmgren, L., Shing, Y., et al. Angiostatin: A circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb. Symp. Quant. Biol. 59: 471, 1994.
126. Lucas, R., Holmgren, L., Garcia, I., et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 92: 4730, 1998.
127. Ito, H., Rovira, I. I., Bloom, M. L., et al. Endothelial progenitor cells as putative targets for angiostatin. Cancer Res. 59: 5875, 1999.
128. Zhang, Z. G., Zhang, L., Jiang, Q., and Chopp, M. Bone marrow-derived endothelial progenitor cells participate in cerebral neovascularization after focal cerebral ischemia in the adult mouse. Circ. Res. 90: 284, 2002.
129. Luttun, A., Carmeliet, G., and Carmeliet, P. Vascular progenitors: From biology to treatment. Trends Cardiovasc. Med. 12: 88, 2002.
130. Zavazava, N., and Kabelitz, D. Alloreactivity and apoptosis in graft rejection and transplantation tolerance. J. Leukoc. Biol. 68: 167, 2000.
131. Kabelitz, D. Apoptosis, graft rejection, and transplantation tolerance. Transplantation 65: 869, 1998.
132. Kanzler, S., and Galle, P. R. Apoptosis and the liver. Semin. Cancer Biol. 10: 173, 2000.
133. Bilbao, G., Contreras, J. L., Gomez-Navarro, J., et al. Genetic modification of liver grafts with an adenoviral vector encoding the Bcl-2 gene improves organ preservation. Transplantation 67: 775, 1999.
134. Fujino, M., Li, X. K., Suda, T., et al. In vitro prevention of cell-mediated xeno-graft rejection via the Fas/FasL-pathway in CrmA-transducted porcine kidney cells. Xenotransplantation 8: 115, 2001.
135. Schierle, G. S., Hansson, O., Leist, M., Nicotera, P., Widner, H., and Brundin, P. Caspase inhibition reduces apoptosis and increases survival of nigral transplants. Nat. Med. 5: 97, 1999.
136. Mackinnon, S. E., Doolabh, V. B., Novak, C. B., and Trulock, E. P. Clinical outcome following nerve allograft transplantation. Plast. Reconstr. Surg. 107: 1419, 2001.
137. Strome, M., Stein, J., Esclamado, R., et al. Laryngeal transplantation and 40-month follow-up. N. Engl. J. Med. 344: 1676, 2001.
138. Foucher, G. Prospects for hand transplantation. Lancet 353: 1286, 1999.
139. Kim, S. K., Aziz, S., Oyer, P., and Hentz, V. R. Use of cyclosporin A in allotransplantation of rat limbs. Ann. Plast. Surg. 12: 249, 1984.
140. Prabhune, K. A., Gorantla, V. S., Maldonado, C., Perez-Abadia, G., Barker, J. H., and Ildstad, S. T. Mixed allogeneic chimerism and tolerance to composite tissue allografts. Microsurgery 20: 441, 2000.
141. Fulda, S., Sieverts, H., Friesen, C., Herr, I., and Debatin, K. M. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 57: 3823, 1997.
142. Marzo, I., Brenner, C., Zamzami, N., et al. The permeability transition pore complex: A target for apoptosis regulation by caspases and bcl-2-related proteins. J. Exp. Med. 187: 1261, 1998.
143. Robertson, J. D., Gogvadze, V., Zhivotovsky, B., and Orrenius, S. Distinct pathways for stimulation of cytochrome c release by etoposide. J. Biol. Chem. 275: 32438, 2000.
144. Laine, J., Etelamaki, P., Holmberg, C., and Dunkel, L. Apoptotic cell death in human chronic renal allograft rejection. Transplantation 63: 101, 1997.
145. Mathes, D. W., Randolph, M. A., and Lee, W. P. Strategies for tolerance induction to composite tissue allografts. Microsurgery 20: 448, 2000.
146. Foster, R. D., Fan, L., Neipp, M., et al. Donor-specific tolerance induction in composite tissue allografts (corrected; erratum to be published). Am. J. Surg. 176: 418, 1998.
147. Kann, B. R., Furnas, D. W., and Hewitt, C. W. Past, present, and future research in the field of composite tissue allotransplantation. Microsurgery 20: 393, 2000.
148. Gastman, B. R., Johnson, D. E., Whiteside, T. L., and Rabinowich, H. Tumor-induced apoptosis of T lymphocytes: Elucidation of intracellular apoptotic events. Blood 95: 2015, 2000.
149. Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A., and Duke, R. C. A role for CD95 ligand in preventing graft rejection. Nature 377: 630, 1995.
150. Swenson, K. M., Ke, B., Wang, T., et al. Fas ligand gene transfer to renal allografts in rats: Effects on allograft survival. Transplantation 65: 155, 1998.
151. Okamoto, K., Asahara, H., Kobayashi, T., et al. Induction of apoptosis in the rheumatoid synovium by Fas ligand gene transfer. Gene Ther. 5: 331, 1998.
152. Lau, H. T., Yu, M., Fontana, A., and Stoeckert, C. J., Jr. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273: 109, 1996.
153. Kang, S. M., Schneider, D. B., Lin, Z., et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction (see comments). Nat. Med. 3: 738, 1997.
154. Nelson, D. P., Setser, E., Hall, D. G., et al. Proinflammatory consequences of transgenic fas ligand expression in the heart. J. Clin. Invest. 105: 1199, 2000.
155. Ashkenazi, A., Pai, R. C., Fong, S., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104: 155, 1999.
156. Phillips, T. A., Ni, J., Pan, G., et al. TRAIL (Apo-2L) and TRAIL receptors in human placentas: Implications for immune privilege. J. Immunol. 162: 6053, 1999.
157. Lawrence, D., Shahrokh, Z., Marsters, S., et al. Differential hepatocyte toxicity of recombinant Apo2L/ TRAIL versions. Nat. Med. 7: 383, 2001.
158. Greenhalgh, D. G. The role of apoptosis in wound healing. Int. J. Biochem. Cell Biol. 30: 1019, 1998.
159. Edwards, M., and Jones, D. Programmed cell death in human acute cutaneous wounds. J. Cutan. Pathol. 28: 151, 2001.
160. Shah, M., Foreman, D. M., and Ferguson, M. W. Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta. Lancet 339: 213, 1992.
161. Chipuk, J. E., Bhat, M., Hsing, A. Y., Ma, J., and Daniel-pour, D. Bcl-xL blocks transforming growth factor-beta 1-induced apoptosis by inhibiting cytochrome c release and not by directly antagonizing Apaf-1-dependent caspase activation in prostate epithelial cells. J. Biol. Chem. 276: 26614, 2001.
162. Kim, S. G., Kim, S. N., Jong, H. S., et al. Caspase-mediated Cdk2 activation is a critical step to execute transforming growth factor-beta1-induced apoptosis in human gastric cancer cells. Oncogene 20: 1254, 2001.
163. Brown, D. L., Kao, W. W., and Greenhalgh, D. G. Apoptosis down-regulates inflammation under the advancing epithelial wound edge: Delayed patterns in diabetes and improvement with topical growth factors. Surgery 121: 372, 1997.
164. Slomiany, B. L., Piotrowski, J., and Slomiany, A. Role of basic fibroblast growth factor in the suppression of apoptotic caspase-3 during chronic gastric ulcer healing. J. Physiol. Pharmacol. 49: 489, 1998.
165. Robson, M. C., Phillips, L. G., Thomason, A., Robson, L. E., and Pierce, G. F. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet 339: 23, 1992.
166. Yao, R., and Cooper, G. M. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 267: 2003, 1995.
167. Desmouliere, A., Redard, M., Darby, I., and Gabbiani, G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am. J. Pathol. 146: 56, 1995.
168. Luo, S., Benathan, M., Raffoul, W., Panizzon, R. G., and Egloff, D. V. Abnormal balance between proliferation and apoptotic cell death in fibroblasts derived from keloid lesions. Plast. Reconstr. Surg. 107: 87, 2001.
169. Sayah, D. N., Soo, C., Shaw, W. W., et al. Downregulation of apoptosis-related genes in keloid tissues. J. Surg. Res. 87: 209, 1999.
170. Grossman, D., Kim, P. J., Blanc-Brude, O. P., et al. Transgenic expression of survivin in keratinocytes counteracts UVB- induced apoptosis and cooperates with loss of p53. J. Clin. Invest. 108: 991, 2001.
171. Borradori, L., and Sonnenberg, A. Structure and function of hemidesmosomes: More than simple adhesion complexes. J. Invest. Dermatol. 112: 411, 1999.
172. Larjava, H., Salo, T., Haapasalmi, K., Kramer, R. H., and Heino, J. Expression of integrins and basement membrane components by wound keratinocytes. J. Clin. Invest. 92: 1425, 1993.
173. Shaw, L. M., Rabinovitz, I., Wang, H. H., Toker, A., and Mercurio, A. M. Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion. Cell 91: 949, 1997.
174. Wolf, G. T., and Carey, T. E. Tumor antigen phenotype, biologic staging, and prognosis in head and neck squamous carcinoma. J. Natl. Cancer Inst. Monogr. 13: 67, 1992.
175. Galiano, R. D., Zhao, L. L., Clemmons, D. R., Roth, S. I., Lin, X., and Mustoe, T. A. Interaction between the insulin-like growth factor family and the integrin receptor family in tissue repair processes: Evidence in a rabbit ear dermal ulcer model. J. Clin. Invest. 98: 2462, 1996.
176. Zhang, Z., Vuori, K., Reed, J. C., and Ruoslahti, E. The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc. Natl. Acad. Sci. U.S.A. 92: 6161, 1995.
177. Pittenger, M. F., Mackay, A. M., Beck, S. C., et al. Multilineage potential of adult human mesenchymal stem cells. Science 284: 143, 1999.
178. Vacanti, J. P., and Langer, R. Tissue engineering: The design and fabrication of living replacement devices for surgical reconstruction and transplantation. Lancet 354 (Suppl. 1): S132, 1999.
179. Marler, J. J., Guha, A., Rowley, J., et al. Soft-tissue augmentation with injectable alginate and syngeneic fibroblasts. Plast. Reconstr. Surg. 105: 2049, 2000.
180. Oreffo, R. O., and Triffitt, J. T. Future potentials for using osteogenic stein cells and biomaterials in orthopedics. Bone 25: 5S, 1999.
181. Schliephake, H., Knebel, J. W., Aufderheide, M., and Tauscher, M. Use of cultivated osteoprogenitor cells to increase bone formation in segmental mandibular defects: An experimental pilot study in sheep. Int. J. Oral Maxillofac. Surg. 30: 531, 2001.
182. Casabona, F., Martin, I., Muraglia, A., et al. Prefabricated engineered bone flaps: An experimental model of tissue reconstruction in plastic surgery. Plast. Reconstr. Surg. 101: 577, 1998.
183. Quarto, R., Mastrogiacomo, M., Cancedda, R., et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. N. Engl. J. Med. 344: 385, 2001.
184. Mankani, M. H., Krebsbach, P. H., Satomura, K., Kuznetsov, S. A., Hoyt, R., and Robey, P. G. Pedicled bone flap formation using transplanted bone marrow stromal cells. Arch. Surg. 136: 263, 2001.
185. Bianco, P., and Robey, P. G. Stem cells in tissue engineering. Nature 414: 118, 2001.
186. Weissman, I. L. Translating stem and progenitor cell biology to the clinic: Barriers and opportunities. Science 287: 1442, 2000.
187. Ohgushi, H., and Caplan, A. I. Stem cell technology and bioceramics: From cell to gene engineering. J. Biomed. Mater. Res. 48: 913, 1999.
188. Palmer, T. D., Schwartz, P. H., Taupin, P., Kaspar, B., Stein, S. A., and Gage, F. H. Cell culture: Progenitor cells from human brain after death. Nature 411: 42, 2001.
189. Zuk, P. A., Zhu, M., Mizuno, H., et al. Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng. 7: 211, 2001.
190. Krause, D. S., Theise, N. D., Collector, M. I., et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 105: 369, 2001.
191. Fuchs, J. R., Nasseri, B. A., and Vacanti, J. P. Tissue engineering: A 21st century solution to surgical reconstruction. Ann. Thorac. Surg. 72: 577, 2001.
192. Donovan, P. J., and Gearhart, J. The end of the beginning for pluripotent stem cells. Nature 414: 92, 2001.
193. Mazel, S., Burtrum, D., and Petrie, H. T. Regulation of cell division cycle progression by bcl-2 expression: A potential mechanism for inhibition of programmed cell death. J. Exp. Med. 183: 2219, 1996.
194. Domen, J., Cheshier, S. H., and Weissman, I. L. The role of apoptosis in the regulation of hematopoietic stem cells: Overexpression of Bcl-2 increases both their number and repopulation potential. J. Exp. Med. 191: 253, 2000.
195. Vogel, G. Stem cell policy: An embryonic alternative. Science 292: 1822, 2001.
196. Johnson, F. B., Sinclair, D. A., and Guarente, L. Molecular biology of aging. Cell 96: 291, 1999.
197. Kajstura, J., Cheng, W., Sarangarajan, R., et al. Necrotic and apoptotic myocyte cell death in the aging heart of Fischer 344 rats. Am. J. Physiol. 271: H1215, 1996.
198. Miller, R. A. The aging immune system: Primer and prospectus. Science 273: 70, 1996.
199. McLeod, J. D. Apoptotic capability in ageing T cells. Mech. Ageing Dev. 121: 151, 2000.
200. Schindowski, K., Leutner, S., Muller, W. E., and Eckert, A. Age-related changes of apoptotic cell death in human lymphocytes. Nuerobiol. Aging 21: 661, 2000.
201. Aggarwal, S., and Gupta, S. Increased apoptosis of T cell subsets in aging humans: Altered expression of Fas (CD95), Fas ligand, Bcl-2, and Bax. J. Immunol. 160: 1627, 1998.
202. Aggarwal, S., Gollapudi, S., and Gupta, S. Increased TNF-alpha-induced apoptosis in lymphocytes from aged humans: Changes in TNF-alpha receptor expression and activation of caspases. J. Immunol. 162: 2154, 1999.
203. Vogelstein, B., Lane, D., and Levine, A. J. Surfing the p53 network. Nature 408: 307, 2000.
204. Tyner, S. D., Venkatachalam, S., Choi, J., et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 415: 45, 2002.
205. Rohrich, R. J. The anti-aging revolution: All evolving role for
206. Puca, A. A., Daly, M. J., Brewster, S. J., et al. A genomewide scan for linkage to human exceptional longevity identifies a locus on chromosome 4. Proc. Natl. Acad. Sci. U.S.A. 98: 10505, 2001.
207. Caelles, C., Helmberg, A., and Karin, M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes (see comments). Nature 370: 220, 1994.